Editorial: Community series in the immune escape mechanism and novel immunotherapeutic strategies of leukemia, volume II.
作者信息
Han Yixiang, Li Qianping, Tan Yicheng, Yu Kang, Zhang Shenghui
机构信息
Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
出版信息
Front Immunol. 2024 May 10;15:1426570. doi: 10.3389/fimmu.2024.1426570. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Community series in the immune escape mechanism and novel immunotherapeutic strategies of leukemia, volume II.社论：白血病免疫逃逸机制与新型免疫治疗策略社区系列，第二卷。
Front Immunol. 2024 May 10;15:1426570. doi: 10.3389/fimmu.2024.1426570. eCollection 2024.
2
Editorial: The immune escape mechanism and novel immunotherapeutic strategies of leukemia.社论：白血病的免疫逃逸机制与新型免疫治疗策略
Front Immunol. 2023 Apr 4;14:1188582. doi: 10.3389/fimmu.2023.1188582. eCollection 2023.
3
Targeting the Tumor Microenvironment of Leukemia and Lymphoma.靶向白血病和淋巴瘤的肿瘤微环境
Trends Cancer. 2019 Jun;5(6):351-364. doi: 10.1016/j.trecan.2019.05.001. Epub 2019 Jun 5.
4
Editorial: Overcoming the Immune Microenvironment of Hepatocellular Cancer.社论：克服肝细胞癌的免疫微环境
Front Immunol. 2021 Jun 2;12:707329. doi: 10.3389/fimmu.2021.707329. eCollection 2021.
5
Catch me if you can: how AML and its niche escape immunotherapy.《逃无可逃：AML 及其生态位如何逃避免疫疗法》
Leukemia. 2022 Jan;36(1):13-22. doi: 10.1038/s41375-021-01350-x. Epub 2021 Jul 23.
6
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.利用PD-L1特异性细胞毒性T细胞进行抗白血病免疫治疗，以对抗由PD-1途径介导的免疫逃逸机制。
Leukemia. 2014 Jan;28(1):236-8. doi: 10.1038/leu.2013.261. Epub 2013 Sep 12.
7
Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.成纤维细胞助力肿瘤微环境中的免疫逃逸。
Trends Cancer. 2019 Nov;5(11):704-723. doi: 10.1016/j.trecan.2019.09.009. Epub 2019 Oct 29.
8
Born to survive: how cancer cells resist CAR T cell therapy.天生的幸存者：癌细胞如何抵抗 CAR T 细胞疗法。
J Hematol Oncol. 2021 Nov 22;14(1):199. doi: 10.1186/s13045-021-01209-9.
9
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中的免疫逃逸机制及其临床相关性。
Int J Mol Sci. 2020 Sep 24;21(19):7032. doi: 10.3390/ijms21197032.
10
Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.社论：旨在增强基于自然杀伤细胞的癌症免疫疗法的分子策略
Front Immunol. 2020 Jun 16;11:1132. doi: 10.3389/fimmu.2020.01132. eCollection 2020.
本文引用的文献
1
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.HA-1 靶向 T 细胞受体 T 细胞疗法治疗造血干细胞移植后复发性白血病。
Blood. 2024 Sep 5;144(10):1069-1082. doi: 10.1182/blood.2024024105.
2
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.序贯 CD7 CAR T 细胞治疗与异基因造血干细胞移植而不进行移植物抗宿主病预防。
N Engl J Med. 2024 Apr 25;390(16):1467-1480. doi: 10.1056/NEJMoa2313812.
3
Escape from T-cell-targeting immunotherapies in acute myeloid leukemia.急性髓系白血病中 T 细胞靶向免疫疗法的逃逸。
Blood. 2024 Jun 27;143(26):2689-2700. doi: 10.1182/blood.2023019961.
4
Acute myeloid leukaemia.急性髓细胞白血病。
Lancet. 2023 Jun 17;401(10393):2073-2086. doi: 10.1016/S0140-6736(23)00108-3. Epub 2023 Apr 15.
5
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.在 PD-1 阻断治疗背景下，对 AML 的单细胞 T 细胞景观和 T 细胞受体库进行分析。
Nat Commun. 2021 Oct 18;12(1):6071. doi: 10.1038/s41467-021-26282-z.
6
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.移植后复发髓系恶性肿瘤中 CTLA-4 阻断的分子和细胞特征。
Blood. 2021 Jun 10;137(23):3212-3217. doi: 10.1182/blood.2021010867.
7
Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review.胸腺功能与癌症发展、复发和抗肿瘤免疫的关联——综述。
Front Immunol. 2020 Apr 30;11:773. doi: 10.3389/fimmu.2020.00773. eCollection 2020.
8
Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.开发 T 细胞免疫疗法，用于有白血病复发风险的造血干细胞移植受者。
Blood. 2018 Jan 4;131(1):108-120. doi: 10.1182/blood-2017-07-791608. Epub 2017 Oct 19.
9
Elevated frequencies of CD4⁺ CD25⁺ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia.CD4⁺ CD25⁺ CD127lo 调节性 T 细胞频率升高与急性髓系白血病患者预后不良相关。
Int J Cancer. 2011 Sep 15;129(6):1373-81. doi: 10.1002/ijc.25791. Epub 2011 Feb 26.
Zotero 插件